Skip to content

News

Visit Confluence at SLAS 2019 Conference, Feb. 2-6, Washington, D.C.

Confluence’s team is attending the SLAS 2019 Conference and Expo. Please visit us at Booth #546. With an expected audience of more than 5,000 top researchers, engineers, academics and other life sciences discovery and technology professionals, SLAS 2019 is focused on Innovation and Application. Come learn about how Confluence can be your research partner from…

[Read More…]

Confluence welcomes William Taylor Ph.D. as Confluence’s new Director of Biochemistry

Dr. Taylor is an accomplished biochemist and drug discovery scientist with a history of providing strategic leadership and critical analyses across multiple target classes & disease areas. Prior to Confluence Discovery Technologies he spent seventeen years at Vertex Pharmaceuticals where he gained extensive experience in bringing small molecules forward from initial screen through hit-to- lead…

[Read More…]
Aclaris Therapeutics Kinase

Aclaris Therapeutics Acquires Confluence Life Sciences, Inc.

Expands pipeline of medicines for the potential treatment of patients with autoimmune disorders Management to Host Conference Call at 8:30 AM ET today MALVERN, Pa., Aug. 08, 2017 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (“Aclaris”) (NASDAQ:ACRS), a dermatologist-led, biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs…

[Read More…]

A Brief History of Tofacitinib

John LaMattina, FORBES CONTRIBUTOR In the summer of 1993, Dr. Paul Changelian, a scientist in Pfizer’s immune suppression group, was looking for a new way to prevent organ transplant rejection. Paul, always on the lookout for new ideas, particularly ones related to suppressing an overactive immune systems (a hallmark of diseases like psoriasis and rheumatoid…

[Read More…]
Scroll To Top